Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML December 8, 2025 12:30 PM EST
Company Participants
Troy Wilson – Chairman, CEO & President
Mollie Leoni – Chief Medical Officer
Conference Call Participants
Amer Zeidan
Eunice Wang
Li Wang Watsek – Cantor Fitzgerald & Co., Research Division
Jiale Song – Jefferies LLC, Research Division
Jonathan Chang – Leerink Partners LLC, Research Division
Peter Green – LifeSci Capital, LLC, Research Division
Etzer Darout – Barclays Bank PLC, Research Division
Hunter Hurley
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Erik Lavington – Mizuho Securities USA LLC, Research Division
Jason Zemansky – BofA Securities, Research Division
Philip Nadeau – TD Cowen, Research Division
Xiaochuan Dai – UBS Investment Bank, Research Division
Presentation
Operator
Good day, everyone. My name is Abigail, and I will be your conference operator today. At this time, I would like to welcome you to the Kura ASH 2025 Update Call. [Operator Instructions]
At this time, I would like to turn the call over to Troy Wilson, President and CEO of Kura Oncology. Dr. Wilson. Please go ahead.
Troy Wilson
Chairman, CEO & President
Thank you, Abigail, and good afternoon, everyone. Welcome to our ASH 2025 analyst and investor event. This is — this has been a big day, and it’s been a great conference for menin inhibitors in acute leukemia. If we can go to the next slide.
We’re going to be making certain forward-looking statements today in the presentation. And I would just refer you either to our website or to the SEC’s website for more information about Kura Oncology and about the risks and certain investment in the company.
If we can go to Slide 3. Here, you can see the agenda. Today, we’re going to be reviewing the data that was actually just presented in the oral session here at ASH. That